Moderna has partnered with Swiss drug manufacturer Lonza to meet demand for its experimental COVID-19 vaccine. The deal will enable Moderna to make 1 billion doses of its potential vaccine per year, assuming the vaccine succeeds in clinical trials. (BioPharma Dive)

Researchers predict the coronavirus outbreak could last up to two years. The scientists mapped out three possible scenarios for COVID-19 going forward. They also stressed that the virus was more contagious than the flu and was likely to continue circulating after the first wave this spring. (CNBC)

Facebook’s coronavirus misinformation effort may be taking the wrong approach, experts said. The social media platform’s strategy is based on psychology research, but experts believe Facebook may be interpreting the findings incorrectly. (STAT)

Gilead CEO committed to making its potential coronavirus treatment affordable and accessible. CEO Daniel O’Day said the company will need to develop a “sustainable model” for the drug, remdesivir. The company previously said it would donate 1.5 million doses of the treatment, if approved. (CNBC)

The next MM&M Convene webcast, COVID-19: Communicating in the Coronavirus Era, takes place on May 14. Register for sessions on reaching HCPs during the crisis, patient engagement, employee engagement and more. (MM&M)